Published Aug 19, 2019

Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma

Member News
Copy The Link to the  Article
Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Copy The Link to the  Article

Related or similar articles

View more News
May 17, 2024

Streamlining Procurement: Labshares Partners with Labviva for Enhanced Access and Efficiency

In the fast-paced world of biotech innovation, easy access to crucial resources is vital for research success. That's why Labshares is excited to share news of our partnership with Labviva, a top procurement platform reshaping how scientists obtain l
Labshares News
June 18, 2024

Labshares Announces Key Leadership Additions: Devon Lagasse Joins as VP of Growth and Emma Orfanos Is Promoted to Manager of Business Development

Press Releases
March 20, 2025

Labshares x BYTE51: A Game-Changing Partnership to Navigate Fundraising

Labshares News